Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H14O3 |
Molecular Weight | 254.2806 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(=O)C1=CC=C(C=C1)C2=CC=CC=C2
InChI
InChIKey=ZPAKPRAICRBAOD-UHFFFAOYSA-N
InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
DescriptionSources: www.ncbi.nlm.nih.gov/pubmed/6356910Curator's Comment: description was created based on several sources, including, http://scialert.net/fulltext/?doi=ajb.2007.50.57
Sources: www.ncbi.nlm.nih.gov/pubmed/6356910
Curator's Comment: description was created based on several sources, including, http://scialert.net/fulltext/?doi=ajb.2007.50.57
Fenbufen is a nonsteroidal anti-inflammatory drug, developed for the treatment of symptoms associated with such disease as rheumatoid arthritis. Fenbufen acts through its active metabolite, 4-biphenylacetic acid which is a potent inhibitor of COX1 and COX2 enzymes. Fenbufen was found to cause skin rash and liver toxicity and was withdrawn from the market.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/6356910 |
3.9 µM [IC50] | ||
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/6356910 |
8.1 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Assessment of temafloxacin neurotoxicity in rodents. | 1991 Dec 30 |
|
[Effects of drugs on the convulsions induced by the combination of a new quinolone antimicrobial, enoxacin, and a nonsteroidal anti-inflammatory drug, fenbufen, in mice]. | 1992 Oct |
|
Role of nitric oxide in the convulsions following the coadministration of enoxacin with fenbufen in mice. | 1998 Apr |
|
Determination of nonsteroidal anti-inflammatory drugs in biological fluids by automatic on-line integration of solid-phase extraction and capillary electrophoresis. | 2001 Feb |
|
[Colitis enhances the colorectal carcinogenesis in rats: correlation between the incidence of aberrant crypt foci and the incidence of tumors]. | 2001 May |
|
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. | 2001 May-Jun |
|
Evaluation of the malignant potential of aberrant crypt foci by immunohistochemical staining for beta-catenin in inflammation-induced rat colon carcinogenesis. | 2002 Apr |
|
Syntheses and reactions of some new 2-arylidene-4-(biphenyl-4-yl)-but-3-en-4-olides with a study of their biological activity. | 2002 Jul |
|
[Surveillance on concurrent administration of quinolones and anti-inflammatory drugs in a community hospital]. | 2003 Aug |
|
Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system. | 2003 Feb |
|
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. | 2003 Jun 2 |
|
The stereospecificity of flobufen metabolism in isolated guinea pig hepatocytes. | 2003 Jun 5 |
|
Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. | 2004 Aug 2 |
|
In vitro reactivity of carboxylic acid-CoA thioesters with glutathione. | 2004 Jan |
|
Inclusion complex of fenbufen with beta-cyclodextrin. | 2004 Mar |
|
Practical synthesis of fenbufen ethanolamide. | 2004 Oct |
|
In-tube solid phase microextraction using a beta-cyclodextrin coated capillary coupled to high performance liquid chromatography for determination of non-steroidal anti-inflammatory drugs in urine samples. | 2005 Jan 15 |
|
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. | 2005 Nov 29 |
|
Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs. | 2006 Aug |
|
Changes in brain interleukin-1beta following the coadministration of norfloxacin with biphenylacetic acid in rats. | 2006 Aug 14 |
|
Contribution of solid-state properties to the aqueous solubility of drugs. | 2006 Nov |
|
Combination of solid-phase extraction and large-volume stacking with polarity switching in micellar electrokinetic capillary chromatography for the determination of traces of nonsteroidal anti-inflammatory drugs in saliva. | 2008 Jul |
|
Thermodynamic studies of Fenbufen, Diflunisal, and Flurbiprofen: sublimation, solution and solvation of biphenyl substituted drugs. | 2008 Jun 5 |
|
Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells. | 2009 |
|
In vitro genotoxic assessment of xenobiotic diacylglycerols in an in vitro micronucleus assay. | 2009 May |
|
Differences in the interaction between aryl propionic acid derivatives and poly(vinylpyrrolidone) K30: A multi-methodological approach. | 2009 Nov |
|
Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. | 2010 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.drugfuture.com/mt/fenbufen.pdf
900 mg daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
||
|
WHO-ATC |
M01AE05
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
||
|
WHO-VATC |
QM01AE05
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID9023043
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL277522
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
31599
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
m5266
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
36330-85-5
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
100000081264
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
9815R1WR9B
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
1145
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
SUB07543MIG
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
C010725
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
757812
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
3439
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
DB08981
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
Fenbufen
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
3335
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
252-979-0
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | |||
|
24830
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
C80548
Created by
admin on Fri Dec 15 15:25:23 GMT 2023 , Edited by admin on Fri Dec 15 15:25:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY